These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9163560)

  • 21. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole.
    Takata K; Kitamura Y; Kakimura J; Kohno Y; Taniguchi T
    Brain Res; 2000 Jul; 872(1-2):236-41. PubMed ID: 10924701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
    Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decrease of prolactin secretion via stimulation of pituitary dopamine D-2 receptors after application of talipexole and SND 919.
    Domae M; Yamada K; Hanabusa Y; Matsumoto S; Furukawa T
    Eur J Pharmacol; 1990 Apr; 179(1-2):75-82. PubMed ID: 2142088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible involvement of differing classes of dopamine D-2 receptors in yawning and stereotypy in rats.
    Yamada K; Nagashima M; Kimura H; Matsumoto S; Furukawa T
    Psychopharmacology (Berl); 1990; 100(2):141-4. PubMed ID: 1968276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
    Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
    Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys.
    Rowlett JK; Platt DM; Yao WD; Spealman RD
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1135-43. PubMed ID: 17351103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H
    Exp Neurol; 1999 Aug; 158(2):414-21. PubMed ID: 10415147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia.
    Waszczak BL; Martin LP; Finlay HE; Zahr N; Stellar JR
    J Pharmacol Exp Ther; 2002 Mar; 300(3):850-61. PubMed ID: 11861790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958.
    Grondin R; Goulet M; Morissette M; Bédard PJ; Di Paolo T
    Eur J Pharmacol; 1999 Aug; 378(3):259-63. PubMed ID: 10493101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model.
    Kitamura Y; Kakimura J; Taniguchi T
    Jpn J Pharmacol; 1998 Sep; 78(1):23-9. PubMed ID: 9804058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
    Andringa G; Vermeulen RJ; Drukarch B; Renier WO; Stoof JC; Cools AR
    Behav Pharmacol; 1999 Mar; 10(2):163-73. PubMed ID: 10780829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative studies on antiparkinsonian agents, talipexole and bromocriptine, evaluated by contralateral rotational behavior in unilaterally nigral-lesioned rats].
    Hironaka N; Kohno Y; Yanagita T
    Nihon Yakurigaku Zasshi; 1998 Oct; 112(4):257-66. PubMed ID: 9866843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylcholine receptor effects on accumbal shell dopamine-mediated turning behaviour in rats.
    Moribe S; Ikeda H; Sato M; Akiyama G; Matsuzaki S; Hasegawa K; Koshikawa N; Cools AR
    Neuropharmacology; 2005 Sep; 49(4):514-24. PubMed ID: 15935407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
    Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
    J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo.
    Carter AJ; Müller RE
    Eur J Pharmacol; 1991 Jul; 200(1):65-72. PubMed ID: 1685123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
    Lorenc-Koci E; Wolfarth S
    Eur J Pharmacol; 1999 Nov; 385(1):39-46. PubMed ID: 10594343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
    Ramirez AD; Wong SK; Menniti FS
    Eur J Pharmacol; 2003 Aug; 475(1-3):29-35. PubMed ID: 12954356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.